Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies
Κonstantinos Thomas, Dimitrios Vassilopoulos
Mediterranean Journal of Rheumatology (2020) Vol. 31, Iss. Suppl 1, pp. 129-129
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
G. Fragoulis, Elena Nikiphorou, Mrinalini Dey, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 6, pp. 742-753
Open Access | Times Cited: 112
The infection risks of JAK inhibition
Maryam Adas, Edward Alveyn, Emma Cook, et al.
Expert Review of Clinical Immunology (2021) Vol. 18, Iss. 3, pp. 253-261
Open Access | Times Cited: 59
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
The type of infections and the use of antibiotics among patients with rheumatoid arthritis: A review
Abeer Hamoud Omar Alshammari, Mona Matar Aldhafeeri, Ahmad M. Aldhafeeri, et al.
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 1, pp. 8-14
Open Access | Times Cited: 1
Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
G. Fragoulis, Mrinalini Dey, Sizheng Steven Zhao, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002726-e002726
Open Access | Times Cited: 32
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 32
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 22
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, et al.
Rheumatology International (2023) Vol. 43, Iss. 3, pp. 421-435
Open Access | Times Cited: 19
Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported questionnaire survey: influence of gender, rural–urban gap and north–south gradient
Esam M. Abualfadl, Faten Ismail, Rawhya R. El Shereef, et al.
Rheumatology International (2020) Vol. 41, Iss. 2, pp. 345-353
Open Access | Times Cited: 50
Reverse Shoulder Arthroplasty in Patients with Rheumatoid Arthritis: A Nationwide Analysis
Andrew G. Beauperthuy, N. Linton, Peter A. Falgiano, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 994-994
Open Access
Real-World Evidence for Baricitinib in the Treatment of Rheumatoid Arthritis in Spain: A Systematic Literature Review
J. Rosas, Joaquín Belzunegui, Blanca Hernández‐Cruz, et al.
Advances in Therapy (2025)
Open Access
Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, et al.
Immunity Inflammation and Disease (2025) Vol. 13, Iss. 4
Open Access
Similar Hepatitis B virus reactivation risk for patients with inflammatory arthritis or connective tissue diseases: a multicenter retrospective study
Μαρία Παππά, Alexandra Koutsogianni, Αναστάσιος Καραμανάκος, et al.
Rheumatology International (2025) Vol. 45, Iss. 1
Closed Access
Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review
Nikolaos Kougkas, Athanasia Dara, Eleni Pagkopoulou, et al.
Rheumatology International (2022) Vol. 42, Iss. 10, pp. 1849-1854
Open Access | Times Cited: 12
Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review
Kiyoko Makimoto, Rie Konno, Atsushi Kinoshita, et al.
JBI Evidence Synthesis (2023) Vol. 21, Iss. 5, pp. 835-885
Closed Access | Times Cited: 4
Point prevalence survey of antibiotics use among hospitalised neonates and children in Saudi Arabia: findings and implications
Hind Alosaimi, Mohammed Kanan Alshammari, Mohammad M. Fetyani, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia
Cody Price, John P. M. Wood, I. Ismail, et al.
Pathogens (2024) Vol. 13, Iss. 11, pp. 943-943
Open Access | Times Cited: 1
Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
Nikolaos Tziolos, Emmanouil Karofylakis, Ioannis Grigoropoulos, et al.
Open Forum Infectious Diseases (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study
Mattia Bellan, Lorenza Scotti, Daniela Ferrante, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 11, pp. 2955-2955
Open Access | Times Cited: 6
Emerging role of baricitinib in dermatology practice: All we need to know!
S. Dogra, Shikha Shah, Ayush Sharma, et al.
Indian Dermatology Online Journal (2023) Vol. 14, Iss. 2, pp. 153-153
Open Access | Times Cited: 3
JAK Inhibitors for the Treatment of Axial Spondyloarthritis
Kalliopi Klavdianou, Charalampos Papagoras, Xenofon Baraliakos
Mediterranean Journal of Rheumatology (2023) Vol. 34, Iss. 2, pp. 129-129
Open Access | Times Cited: 3
Holistic Care of the Immunocompromised Rheumatologic Patient – Case Analysis
Hannah Moir
EMJ Rheumatology (2024), pp. 2-13
Open Access
Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines
Anthony J. Ocon, Shiamak Cooper, Allison Ramsey, et al.
Cureus (2024)
Open Access
Rheumatoid arthritis as an internal disease
Martina Skácelová, Pavel Hořák
Vnitřní lékařství (2024) Vol. 70, Iss. 6, pp. 358-365
Closed Access
COVID-19

Revista Paulista de Reumatologia (2020), Iss. 2020 jul-set;19(3)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top